[go: up one dir, main page]

AR047516A1 - Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparacion y su uso como medicamentos - Google Patents

Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparacion y su uso como medicamentos

Info

Publication number
AR047516A1
AR047516A1 ARP050100321A ARP050100321A AR047516A1 AR 047516 A1 AR047516 A1 AR 047516A1 AR P050100321 A ARP050100321 A AR P050100321A AR P050100321 A ARP050100321 A AR P050100321A AR 047516 A1 AR047516 A1 AR 047516A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
substituted
coo
cooh
Prior art date
Application number
ARP050100321A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004004973A external-priority patent/DE102004004973A1/de
Priority claimed from DE102004033405A external-priority patent/DE102004033405A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR047516A1 publication Critical patent/AR047516A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1) en la que los significados son: R1 OH, O-alquilo C1-6 o O-alquil C1-6-OCO-alquilo C1-6; R2 H, alquilo C1-6 o fenilo; R3 H, alquilo C1-8, cicloalquilo C3-7, piridilo o fenilo, donde el alquilo puede estar sustituido con R9 y donde el fenilo o piridilo puede estar sustituido con R10; R9 NH2, NH-alquilo C1-6, N-(alquilo C1-6)2; COOH, COO-alquilo C1-6, cicloalquilo C3-7, heteroalquilo, heteroarilo, O-fenilo o fenilo, donde el fenilo y el heteroarilo pueden estar sustituidos con R11; R10 F, Cl, Br, alquilo C1-6, O-alquilo C1-6, COOH, COO-alquilo C1-6, NH2, NH-alquilo C1-6 o N-(alquilo C1-6)2; R11 F, Cl, alquilo C1-6, O-alquilo C1-6, NH2, NH-alquilo C1-6, N-(alquilo C1-6)2, COOH o COO-alquilo C1- 4; X C-R4 o N; R4 H, F, Cl, Br, OH, NO2, CN, alquilo C1-6 o O-alquilo C1-6, donde el alquilo puede estar sustituido más de una vez con F, Cl o Br; R5 H, F, Cl, Br, OH, NO2, CN, alquilo C1-6 o O-alquilo C1-6, donde el alquilo puede estar sustituido más de una vez con F, Cl o Br; R6 H, F, Cl, Br, OH, NO2, CN, alquilo C1-6, donde el alquilo puede estar sustituido más de una vez con F, Cl o Br; R7 H o alquilo C1-6; R8 fenilo, donde el fenilo puede estar sustituido hasta cinco veces con F, Cl, Br, CN, NO2, alquilo C1-8, O-alquilo C1-8, S-alquilo C1-8, alquenilo C2-8, cicloalquilo C3-7, CO-alquilo C1-4, fenilo, bencilo, benzoilo, NH2, NH-alquilo C1-6, N-(alquilo C1-6)2, P(O)-(O-alquilo C1-4)2 o heteroalquilo, donde el alquilo y el alquenilo pueden estar sustituidos más de una vez con F, Cl, Br, COOH o COO-alquilo C1-4; heteroalquilo un anillo heterocíclico, saturado o insaturado de 4 a 7 miembros que puede comprender hasta 3 heteroátomos N, O o S como miembros del anillo, donde el anillo puede estar sustituido con F, Cl, Br, CN, NO2, alquilo C1-4, OH, COOH, COO-alquilo C1-4; con la excepcion de los compuestos de la formula (1) en la que los radicales tienen simultáneamente los siguientes significados: X es igual a N, R1 es igual a OH, R2; R3, R4, R5 y R7 son iguales a H y R8 es igual a fenilo sin sustituir; y las sales fisiologicamente aceptables del mismo.
ARP050100321A 2004-01-31 2005-01-28 Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparacion y su uso como medicamentos AR047516A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004004973A DE102004004973A1 (de) 2004-01-31 2004-01-31 7-Phenylamino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004033405A DE102004033405A1 (de) 2004-07-10 2004-07-10 7-Phenylamino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR047516A1 true AR047516A1 (es) 2006-01-25

Family

ID=34828328

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100321A AR047516A1 (es) 2004-01-31 2005-01-28 Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparacion y su uso como medicamentos

Country Status (19)

Country Link
EP (1) EP1713803B1 (es)
JP (1) JP2007519648A (es)
KR (1) KR20060132671A (es)
AR (1) AR047516A1 (es)
AT (1) ATE438645T1 (es)
AU (1) AU2005209365A1 (es)
BR (1) BRPI0507309A (es)
CA (1) CA2554522A1 (es)
DE (1) DE502005007840D1 (es)
EC (1) ECSP066734A (es)
IL (1) IL176913A0 (es)
MA (1) MA28337A1 (es)
OA (1) OA13364A (es)
PA (1) PA8622401A1 (es)
PE (1) PE20051094A1 (es)
RU (1) RU2006131306A (es)
TW (1) TW200533353A (es)
UY (1) UY28732A1 (es)
WO (1) WO2005073229A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200702311A1 (ru) * 2005-04-21 2008-10-30 Тарганта Терапьютикс Инк. Фосфонированные фторхинолоны, их антибактериальные аналоги и способы профилактики и лечения инфекций костей и суставов
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
EP2540722B1 (en) 2006-10-16 2016-06-08 Bionomics Limited Novel anxiolytic compounds
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010073078A2 (en) * 2008-12-22 2010-07-01 Orchid Research Laboratories Ltd. Heterocyclic compounds as hdac inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012116415A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
AU2012253237B2 (en) 2011-05-12 2015-09-24 Bionomics Limited Methods for preparing naphthyridines
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205165D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
TW200533353A (en) 2005-10-16
MA28337A1 (fr) 2006-12-01
EP1713803A1 (de) 2006-10-25
ATE438645T1 (de) 2009-08-15
WO2005073229A1 (de) 2005-08-11
KR20060132671A (ko) 2006-12-21
JP2007519648A (ja) 2007-07-19
BRPI0507309A (pt) 2007-06-26
DE502005007840D1 (de) 2009-09-17
PE20051094A1 (es) 2006-02-07
IL176913A0 (en) 2006-12-10
EP1713803B1 (de) 2009-08-05
CA2554522A1 (en) 2005-08-11
ECSP066734A (es) 2006-10-31
UY28732A1 (es) 2005-08-31
RU2006131306A (ru) 2008-03-10
AU2005209365A1 (en) 2005-08-11
OA13364A (en) 2007-04-13
PA8622401A1 (es) 2005-08-10

Similar Documents

Publication Publication Date Title
AR047516A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparacion y su uso como medicamentos
AR039403A1 (es) Derivados de acil-4-carboxifenilurea y su uso como antidiabetico
AR040477A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos
AR079541A1 (es) Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos
AR082103A1 (es) Derivados de dioxido de 1,3-propano sustituidos de manera espirociclica, composiciones farmaceuticas que los contienen y su uso como agentes antidiabeticos
AR077468A1 (es) Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
JP2016522172A5 (es)
AR082102A1 (es) Derivados de acido (2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
RU2009115498A (ru) Производное бензимидазола и его применение
AR043154A1 (es) Derivados sustituidos con nitrogeno de hexahidro-pirazino[1,2-a] pirimidin-4,7-diona, procedimientos para su preparacion y su uso como medicamentos
CL2008002654A1 (es) Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras.
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
MX2015014336A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
AR078164A1 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos y composiciones farmaceuticas que los comprenden
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
AR064899A1 (es) Uso de derivados de acido de piranona sustituidos para producir medicamentos para tratar el sindrome metabolico
AR075534A1 (es) Derivados de piridazinona sustituida por heteroarilo
RU2010115337A (ru) Трициклические гетероциклические производные
AR049588A1 (es) Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina como inhibidores de receptores ptp1b
AR081966A1 (es) Derivados aminoester de alcaloides y composicion medicinal de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure